{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091199","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.162246+00:00","generated_at":"2026-05-31T12:49:56.442654+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance","bullets":["Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).","Non-GAAP adjusted EBITDA $16.6M (8.4% margin), +310 bps YoY from $9.9M.","Bone Growth Therapies +12% YoY; U.S. Spine Fixation +12% YoY; Global Orthopedics +5%.","FY2024 net sales guidance raised to $795-800M; adjusted EBITDA to $64-69M.","Expects positive free cash flow in H2 2024; appointed four new executive team members."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091199","json":"https://secwatch.observer/filing/0000950170-24-091199.json","markdown":"https://secwatch.observer/filing/0000950170-24-091199.md","text":"https://secwatch.observer/filing/0000950170-24-091199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017024091199/0000950170-24-091199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017024091199/ofix-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:49:56.442654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}